SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Sponsored
After the JPM Hype, a Reality Check: Why your 2026 Strategy Hinges on your Manufacturing Toolkit
After J.P. Morgan, biotech’s bold promises meet real-world challenges. In 2026, success starts with a CDMO partner who accelerates timelines and anticipates every manufacturing hurdle. Learn how AGC Biologics offers tailored cell line solutions for complex molecules.
January 19, 2026
 · 
3 min read
Illustration showing finger pointing people to leave
Layoffs
Vedanta ‘Significantly’ Reduces Staff, Focuses on Phase III Study of C. Diff Drug
Less than six months after cutting 20% of its employees, Vedanta Biosciences has again laid off staff. According to one affected staffer, half of the Cambridge, Massachusetts–based biotech’s workforce is being cut while most of the rest are furloughed.
January 16, 2026
 · 
2 min read
 · 
Angela Gabriel
Vector of a businessman standing at cross his career being offered financial incentives
Business
JPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer
Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development. Hundreds of millions of dollars are on the line.
January 16, 2026
 · 
2 min read
 · 
Annalee Armstrong
Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.
Mergers & acquisitions
Speculation of Sanofi Takeover Sends Ocular’s Stock Soaring
Ocular Therapeutix’s lead asset is Axpaxli, being developed for wet age-related macular degeneration. A Phase III study is underway, with data expected this quarter.
January 16, 2026
 · 
1 min read
 · 
Tristan Manalac
Paper airplanes flying on blue sky and cloud.Paper art style of business teamwork and one different vision creative concept idea.Vector illustration
Mergers & acquisitions
JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
January 16, 2026
 · 
3 min read
 · 
Annalee Armstrong
Fund raising Capital Donation. Funds Support Concept. Fundraising. Collecting donations in jar.
Funding
Novo Foundation Pumps $850M Into Denmark, Europe to Bolster Innovation
The Novo Nordisk Foundation’s funds will go toward supporting early-stage companies working in “human health, planetary health and societal resilience.”
January 16, 2026
 · 
2 min read
 · 
Tristan Manalac
Art collage, hands and scales of justice. The concept of the law of the judge.
Legal
Former Emergent CEO Hit With Insider Trading Lawsuit
Robert Kramer, former CEO of Emergent BioSolutions, allegedly earned more than $10.1 million by executing trades with information related to the company’s manufacturing operations that had yet to be made public.
January 16, 2026
 · 
2 min read
 · 
Tristan Manalac
Top view of successful businessman lost in labyrinth
RNA editing
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop partnerships, pitch the potential of its new AATD program and find more money to keep the dream alive.
January 16, 2026
 · 
3 min read
 · 
Dan Samorodnitsky
Drug pricing
Trump Takes Drug Pricing Fight To Insurers With ‘The Great Healthcare Plan’
Incoming PhRMA Chair Paul Hudson, a day before the White House announcement, pledged to work with the administration as the president turns to insurers as a source of cost savings for prescription medicines.
January 15, 2026
 · 
2 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS